Visionary Horizons LLC Has $636,000 Position in Bristol-Myers Squibb (NYSE:BMY)

Visionary Horizons LLC cut its holdings in Bristol-Myers Squibb (NYSE:BMY) by 14.7% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 10,423 shares of the biopharmaceutical company’s stock after selling 1,796 shares during the quarter. Visionary Horizons LLC’s holdings in Bristol-Myers Squibb were worth $636,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. Truist Financial Corp lifted its position in shares of Bristol-Myers Squibb by 3.9% in the fourth quarter. Truist Financial Corp now owns 1,597,150 shares of the biopharmaceutical company’s stock worth $90,335,000 after purchasing an additional 60,365 shares in the last quarter. Advyzon Investment Management LLC acquired a new stake in Bristol-Myers Squibb in the 4th quarter valued at $458,000. Covenant Asset Management LLC bought a new stake in Bristol-Myers Squibb during the 4th quarter worth about $279,000. Polar Asset Management Partners Inc. acquired a new position in shares of Bristol-Myers Squibb during the 4th quarter worth about $16,651,000. Finally, Kentucky Trust Co acquired a new position in shares of Bristol-Myers Squibb during the 4th quarter worth about $389,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Samit Hirawat bought 4,250 shares of the stock in a transaction dated Friday, April 25th. The shares were bought at an average cost of $47.58 per share, for a total transaction of $202,215.00. Following the purchase, the executive vice president now directly owns 83,513 shares of the company’s stock, valued at approximately $3,973,548.54. This trade represents a 5.36% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.09% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on BMY shares. Piper Sandler initiated coverage on Bristol-Myers Squibb in a research note on Tuesday, April 22nd. They set an “overweight” rating and a $65.00 price objective on the stock. William Blair reaffirmed a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Friday, April 25th. Wall Street Zen cut shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Friday, June 6th. Cantor Fitzgerald restated a “neutral” rating and set a $55.00 price objective on shares of Bristol-Myers Squibb in a research note on Tuesday, April 22nd. Finally, Argus upgraded shares of Bristol-Myers Squibb to a “hold” rating in a research note on Friday, April 25th. Two research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, six have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $58.00.

Bristol-Myers Squibb Stock Performance

Shares of BMY opened at $49.96 on Wednesday. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $63.33. The company has a market cap of $101.66 billion, a PE ratio of -11.30, a P/E/G ratio of 2.07 and a beta of 0.38. The stock has a 50-day moving average of $48.97 and a 200-day moving average of $54.92. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.50 by $0.30. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The firm had revenue of $11.20 billion for the quarter, compared to the consensus estimate of $10.77 billion. During the same quarter in the prior year, the company posted ($4.40) earnings per share. The business’s revenue was down 5.6% on a year-over-year basis. On average, equities research analysts predict that Bristol-Myers Squibb will post 6.74 EPS for the current fiscal year.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.